Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kymera Therapeutics (KYMR) Return on Sales (2019 - 2026)

Kymera Therapeutics (KYMR) has disclosed Return on Sales for 8 consecutive years, with 2.45% as the latest value for Q1 2026.

  • For Q1 2026, Return on Sales rose 92.0% year-over-year to 2.45%; the TTM value through Mar 2026 reached 6.98%, down 225.0%, while the annual FY2025 figure was 8.92%, 336.0% down from the prior year.
  • Return on Sales hit 2.45% in Q1 2026 for Kymera Therapeutics, up from 34.14% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.4% in Q4 2023 and bottomed at 34.14% in Q4 2025.
  • Average Return on Sales over 5 years is 9.01%, with a median of 4.7% recorded in 2022.
  • On a YoY basis, Return on Sales climbed as much as 226bps in 2025 and fell as far as -2321bps in 2025.
  • Kymera Therapeutics' Return on Sales stood at 2.4% in 2022, then soared by 83bps to 0.4% in 2023, then crashed by -2603bps to 10.93% in 2024, then plummeted by -212bps to 34.14% in 2025, then soared by 93bps to 2.45% in 2026.
  • According to Business Quant data, Return on Sales over the past three periods came in at 2.45%, 34.14%, and 33.51% for Q1 2026, Q4 2025, and Q3 2025 respectively.